Skip to main content
AstraZeneca Pharma India Ltd. logo

AstraZeneca Pharma India Ltd. — Investor Relations & Filings

Ticker · ASTRAZEN ISIN · INE203A01020 LEI · 335800N8M7W5JDTAHR68 BSE.NS Manufacturing
Open in API
Filings indexed 1,263 across all filing types
Latest filing 2022-08-08 Interim / Quarterly Rep…
Country IN India
Listing BSE.NS ASTRAZEN

About AstraZeneca Pharma India Ltd.

https://www.astrazeneca.com/content/az-…

AstraZeneca Pharma India Ltd. is a science-led biopharmaceutical organization dedicated to the discovery, development, and commercialization of innovative prescription medicines. The company focuses on core therapeutic areas including Oncology, Cardiovascular, Renal & Metabolism, Respiratory & Immunology, and Rare Disease. Its product portfolio includes advanced treatments such as Tagrisso, Lynparza, and Imfinzi for various cancers, as well as Forxiga and Brilinta for metabolic and cardiovascular conditions. The company utilizes a robust global research pipeline to address complex medical challenges and improve patient outcomes. Through clinical research and specialized healthcare solutions, it delivers transformative therapies designed to treat chronic and life-threatening diseases. The organization is characterized by its commitment to scientific excellence and the delivery of high-value medical interventions.

Recent filings

Filing Released Lang Actions
Outcome of Board Meeting
Interim / Quarterly Report Classification · 100% confidence The document is a letter dated August 8, 2022, from AstraZeneca Pharma India Limited addressed to stock exchanges (BSE and NSE) announcing the outcome of a Board Meeting held on the same date. The key content is the approval of the unaudited financial results for the quarter ended June 30, 2022, accompanied by a Limited Review report from the statutory auditors. The document includes detailed financial data for the quarter, notes on accounting standards, and an auditor's review report. The presence of unaudited quarterly financial results and the auditor's limited review report indicates this is a quarterly financial report. The document is over 10,000 characters, so it is not a mere announcement or publication notice. It contains substantive financial data and analysis for a period shorter than a full fiscal year, consistent with an Interim / Quarterly Report. Therefore, the correct classification is Interim / Quarterly Report (IR). Q1 2023
2022-08-08 English
At the Board meeting of the Company held on Monday, August 8, 2022 the Board of Directors considered and approved the Unaudited Financial Results of the Company for the quarter ended June ....
Interim / Quarterly Report Classification · 100% confidence The document is a letter dated August 8, 2022, from AstraZeneca Pharma India Limited addressed to stock exchanges (BSE and NSE) announcing the outcome of a Board Meeting held on the same date. The key content is the approval of the unaudited financial results for the quarter ended June 30, 2022, accompanied by a Limited Review report from the statutory auditors. The document includes detailed financial data for the quarter, notes on accounting standards, and an auditor's review report. The presence of unaudited quarterly financial results and a limited review report indicates this is a quarterly financial report. The document is over 10,000 characters, so it is not a mere announcement or publication notice. It contains substantive financial data and analysis for a period shorter than a full fiscal year, consistent with an Interim / Quarterly Report. Therefore, the correct classification is Interim / Quarterly Report (IR). Q1 2023
2022-08-08 English
Board Meeting — Financial results
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges informing them about an upcoming Board of Directors meeting scheduled for August 8, 2022, to consider and approve the unaudited financial results for the quarter ended June 30, 2022. It also mentions the closure of the trading window for insiders. The document does not contain the financial results themselves, nor detailed financial data or analysis. It is a notification about a future event (board meeting) and the trading window closure, not the actual financial report or earnings release. The document length is short (1538 characters), and it serves as an announcement rather than a report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such announcements that do not fit other specific categories.
2022-08-01 English
ASTRAZENECA PHARMA INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/08/2022 ,inter alia, to consider and approve This is to inform ....
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges informing them about an upcoming Board of Directors meeting scheduled for August 8, 2022, to consider and approve the unaudited financial results for the quarter ended June 30, 2022. It also mentions the closure of the trading window for insiders. The document does not contain the financial results themselves, nor detailed financial data or analysis. It is a notification about a future event (board meeting and financial results approval). The document length is short (1538 characters), and it serves as an announcement rather than a report. Therefore, it fits best as a Regulatory Filing (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2022-08-01 English
General updates
Regulatory Filings Classification · 95% confidence The document is a certificate pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, issued by the Registrar and Transfer Agent confirming compliance with dematerialization regulations for a specific period (June 1 to June 30, 2022). It is addressed to stock exchanges and signed by the company secretary. The document is short (3268 characters) and primarily serves as a compliance certificate rather than a financial report or announcement of financial results. It does not contain financial statements, management discussion, or audit information. It is a regulatory compliance certificate related to securities and share dematerialization, fitting best under Regulatory Filings (RNS) as it does not fit other specific categories like Annual Report, Interim Report, or Audit Report.
2022-07-20 English
We are enclosing herewith Certificate dated July 4, 2022 issued by Integrated Registry Management Services Private Limited, Registrar and Transfer Agents (RTA) of the Company confirming ....
Regulatory Filings Classification · 95% confidence The document is a certificate pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, issued by the Registrar and Transfer Agent confirming compliance with dematerialization regulations for the period 01.06.2022 to 30.06.2022. It is addressed to stock exchanges and signed by the company secretary. The document is short (3268 characters) and primarily serves as a compliance certificate rather than a financial report or announcement of financial results. It does not contain financial statements, management discussion, or audit information. It is not an announcement of voting results, board changes, or capital changes. It is a regulatory compliance certificate related to securities dematerialization. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory compliance documents that do not fit other specific categories.
2022-07-20 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.